Get the Stockscreener App
8.79
1.57%
-0.14
After Hours:
8.90
0.11
+1.25%
Zevra Therapeutics Inc stock is traded at $8.79, with a volume of 1.10M.
It is down -1.57% in the last 24 hours and up +5.14% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$8.93
Open:
$8.88
24h Volume:
1.10M
Relative Volume:
1.30
Market Cap:
$494.86M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-6.814
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-3.30%
1M Performance:
+5.14%
6M Performance:
-1.79%
1Y Performance:
+14.16%
1-Day Range:
$8.705
$9.11
1-Week Range:
$8.705
$9.24
52-Week Range:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
8.79 | 502.74M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Zevra Therapeutics Appoints New CFO - Intellectia AI
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer - citybiz
Zevra Therapeutics Names Justin Renz CFO - marketscreener.com
25-year biopharma finance leader Justin Renz joins Zevra as CFO - Stock Titan
Royce & Associates LP Takes Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Zevra Therapeutics, Inc. to Announce Fourth Quarter and Full Year 2025 Results on March 9, 2026 - Quiver Quantitative
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call - Yahoo Finance
How Zevra Therapeutics Inc. (ZVRA) Affects Rotational Strategy Timing - Stock Traders Daily
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: Uncovering a Potential 148% Upside in the Biotech Sector - DirectorsTalk Interviews
ZVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Zevra Therapeutics (ZVRA) Pricing Reflect Its Strong DCF Upside Potential? - Yahoo Finance
Rare-disease biotech Zevra heads to Miami for Citizens Life Sciences Conference - Stock Titan
RSI Check: Will Zevra Therapeutics Inc benefit from geopolitical trendsEarnings Summary Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
ZVRAZevra Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: Exploring A Potential 153.59% Upside - DirectorsTalk Interviews
Can Zevra Therapeutics Inc. sustain earnings growthJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - mfd.ru
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - TradingView
(ZVRA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Delaware Chancery Court Holds that Grant of Security Interest is a “Transfer” – Commave v. Zevra | Insights - Mayer Brown
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Update - MarketBeat
Earnings Beat: Can Zevra Therapeutics Inc maintain sales growthJuly 2025 Selloffs & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Can Zevra Therapeutics Inc. stock double in the next yearJuly 2025 Gainers & AI Powered Market Entry Strategies - mfd.ru
What is the next catalyst for Zevra Therapeutics Inc.Weekly Stock Summary & Safe Entry Point Alerts - mfd.ru
Will Zevra Therapeutics Inc. benefit from geopolitical trendsWeekly Trade Analysis & Real-Time Buy Zone Alerts - mfd.ru
Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Unveiling a 168% Potential Upside in Biotechnology - DirectorsTalk Interviews
Neil F. McFarlane, Zevra Therapeutics president, sells $125k in shares - Investing.com Canada
Stock Analysis: What is the implied volatility of Zevra Therapeutics IncEarnings Growth Report & Technical Confirmation Alerts - baoquankhu1.vn
Zevra Therapeutics opens Nasdaq with bell ceremony - Traders Union
Zevra Therapeutics Rings the Opening Bell - Nasdaq
Responsive Playbooks and the ZVRA Inflection - Stock Traders Daily
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: Unpacking a 169.66% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA in Patients with Neimann-Pick Disease Type C at the 22nd Annual WorthLDSymposium - marketscreener.com
ZVRA: Zevra Therapeutics Unveils Promising Data on Miplyffa at W - GuruFocus
Zevra Therapeutics Presents Positive Data on MIPLYFFA® for Niemann-Pick Disease Type C at WORLDSymposium™ 2026 - Quiver Quantitative
Zevra Therapeutics Presents Positive New Real-World Data on - GlobeNewswire
4 years of real-world data track MIPLYFFA in rare Niemann-Pick disease - Stock Titan
Zevra Therapeutics CEO McFarlane sells $853k in shares - Investing.com South Africa
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock By Investing.com - Investing.com UK
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock - Investing.com Nigeria
Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $29,801.25 in Stock - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $40,026.39 in Stock - MarketBeat
Neil Mcfarlane Sells 91,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock - MarketBeat
Insider Selling: Zevra Therapeutics (NASDAQ:ZVRA) SVP Sells 1,750 Shares of Stock - MarketBeat
Zevra Therapeutics CEO McFarlane sells $853k in shares By Investing.com - Investing.com South Africa
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 - The Manila Times
Published on: 2026-02-02 12:45:20 - baoquankhu1.vn
Portfolio Shifts: Can Zevra Therapeutics Inc maintain sales growthJuly 2025 Spike Watch & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Layoff Watch: Does Zevra Therapeutics Inc have declining or rising EPS2025 Growth vs Value & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Down 32.5% in January - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zevra Therapeutics Inc Stock (ZVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller |
Feb 03 '26 |
Sale |
9.18 |
3,000 |
27,548 |
29,590 |
| Schafer Joshua | CCO |
Feb 03 '26 |
Sale |
9.19 |
10,500 |
96,500 |
62,278 |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller |
Jan 30 '26 |
Sale |
8.82 |
1,750 |
15,442 |
20,924 |
| Thompson Rahsaan | Chief Legal & Compliance |
Jan 30 '26 |
Sale |
8.83 |
4,080 |
36,010 |
49,919 |
| Quartel Adrian W | Chief Medical Officer |
Jan 30 '26 |
Sale |
8.83 |
4,533 |
40,036 |
9,723 |
| Schafer Joshua | CCO |
Jan 30 '26 |
Sale |
8.83 |
3,375 |
29,800 |
37,444 |
| McFarlane Neil F. | President and CEO |
Feb 02 '26 |
Sale |
9.38 |
91,000 |
853,425 |
364,350 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):